Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along…